Jeito Capital stands as a pivotal force in the global biopharmaceutical landscape, redefining how innovative medical solutions are brought to patients. Founded with a vision to bridge critical funding gaps, this independent private equity firm is carving a niche by providing substantial, long-term capital and strategic expertise to clinical-stage biopharma companies. Headquartered in Paris, Jeito Capital focuses primarily on the vibrant European ecosystem, nurturing breakthrough therapies for severe diseases with high unmet medical needs. Its recent record-breaking fund closes underscore its growing influence and unique patient-centric investment model, promising to accelerate the development and market access of life-changing medicines. Prepare to delve into the core tenets that make Jeito Capital a noteworthy player in medical innovation.
At the heart of Jeito Capital is its founder and president, Dr. Rafaèle Tordjman. A distinguished physician, hematologist, and former research scientist at INSERM, Dr. Tordjman brings over two decades of experience as a life sciences investor. Her deep scientific and medical background profoundly influences Jeito's patient-benefit-driven investment philosophy, ensuring that funding decisions are rooted in a genuine understanding of medical needs and therapeutic potential. This unique combination of clinical, scientific, and investment expertise forms the bedrock of Jeito's strategic approach to fostering innovation. [3, 5]
Jeito Capital distinguishes itself through a unique investment strategy that moves beyond the traditional "spray-and-pray" venture capital model. Instead, it employs a continuous financing approach, committing significant capital – up to €150 million per company with its latest fund – to a select number of high-potential, clinical-stage biopharma companies. This substantial and sustained financial backing is designed to support companies through critical, often underfunded, clinical development phases (Phase 2 and 3) all the way to market access, accelerating the journey of breakthrough innovations to patients. [4, 12, 18]
On April 8, 2026, Jeito Capital announced the final closing of its second fund, Jeito II, at an impressive €1 billion ($1.2 billion), significantly exceeding its initial target. This achievement marks it as the largest fund ever raised by a fully independent European fund dedicated to biopharma. [1, 4, 8, 9, 12] The success of Jeito II, following the €534 million raised by Jeito I in 2021, tripled the firm's assets under management to €1.6 billion. [4, 9, 11] This monumental fundraising reflects strong investor confidence and signals a robust future for European biopharmaceutical innovation. [1, 8]
Jeito Capital's investment focus is sharply honed on clinical-stage biopharmaceutical companies. These are entities already demonstrating promising early results, developing therapies for severe diseases where current treatments fall short. The firm specifically seeks out companies with high potential for breakthrough innovation, aiming to accelerate their progress through pivotal clinical trials and towards commercialization. By concentrating on this critical stage, Jeito addresses a common funding gap in the European ecosystem, propelling promising drug candidates closer to patients. [1, 12, 18]
While maintaining a global outlook, Jeito Capital places a significant emphasis on the European biopharma sector. It recognizes Europe's rich scientific talent and innovative research landscape but also the historical challenge of securing long-term, substantial capital for scaling companies. Jeito's substantial funds, particularly Jeito II, are explicitly designed to empower European biopharma companies to develop into global leaders, reducing the need for them to seek public listings or acquisitions outside the continent. [4, 9, 13]
Jeito Capital strategically invests across a diverse range of therapeutic areas, all unified by the common thread of high unmet medical needs. Its portfolio includes companies developing innovative treatments for conditions such as immuno-oncology, ophthalmology, cardiology, severe respiratory diseases, fibrosis, and associated cancers. More recent investments under Jeito II have expanded into areas like obesity, reproductive medicine, autoimmune, inflammatory diseases, and neurology, underscoring its commitment to addressing a broad spectrum of critical health challenges globally. [3, 4, 8, 9]
A core strength of Jeito Capital lies in its multidisciplinary and integrated team of experts. This team encompasses professionals with extensive experience across the entire drug value chain, from translational science and clinical development to regulatory affairs, manufacturing, and market access. This comprehensive internal expertise allows Jeito to offer more than just capital; it provides hands-on strategic and operational support, guiding portfolio companies through complex development processes and helping them achieve their full commercial potential. [2, 3, 5, 9]
Jeito Capital has already demonstrated a strong track record of successful exits, validating its investment strategy. Notably, three of its portfolio companies have been acquired by major pharmaceutical players. Neogene, a cancer drugmaker, was acquired by AstraZeneca for $200 million in 2022. EyeBio, an eye drug developer, was purchased by Merck & Co. for up to $3 billion in 2024. [1, 4, 9, 20] Additionally, Hi-Bio, an immunology company, was acquired by Biogen for up to $1.8 billion in the same year. [1, 4, 9] These exits highlight Jeito's ability to identify and nurture companies that deliver significant value and therapeutic innovation.
Beyond its investment activities, Dr. Rafaèle Tordjman is also a champion for gender equality in the life sciences. In 2010, she founded W.I.T.H. (Women Innovating Together in Healthcare), an association aimed at engaging and empowering women in the industry. [2, 5] This initiative, now boasting a global membership of 500 women, demonstrates Jeito Capital's commitment to broader societal impact and fostering diversity within the medical innovation ecosystem, aligning with its patient-centric ethos by recognizing diverse perspectives in healthcare leadership.
Headquartered in Paris, Jeito Capital maintains a strong European identity, positioning itself as a crucial player in supporting the continent's biopharma growth. However, its ambition extends globally, with a presence and investment strategy that also considers the United States market. [5, 7] This dual focus allows Jeito to leverage European scientific excellence while ensuring that the innovative therapies it backs have the potential for worldwide impact and accelerated patient access, solidifying its role as a key contributor to global medical advancement. [3, 7]
Jeito Capital has rapidly emerged as a transformative force in the biopharmaceutical investment sphere. Under the astute leadership of Dr. Rafaèle Tordjman, the firm has not only successfully raised significant capital, including the record-breaking Jeito II fund, but has also deployed it strategically to nurture clinical-stage companies developing groundbreaking therapies for critical unmet medical needs. Its unique, patient-centric approach, combined with deep industry expertise and a commitment to fostering European innovation, positions Jeito Capital as a catalyst for accelerating medical breakthroughs. As it continues to expand its portfolio and deliver successful exits, Jeito Capital remains dedicated to its mission of bringing life-changing medicines to patients worldwide, promising continued impact on global health. What future therapeutic areas might benefit most from Jeito Capital's distinctive investment model?
No sources were returned from search grounding.
